Expansion of medical devices beyond the cardiovascular field and entry into the gastrointestinal field

「Sales of gastrointestinal products amounted to ¥494 million (up 29.9% year on year).」

「In the fiscal year ending March 2026, the company launched a new double-pigtail model of its bile duct tube stent, making a significant contribution to increased awareness of its own brand and sales growth. It also launched new products including a bile duct dilation balloon and a double-lumen dilator, and newly obtained regulatory approval for a bile duct stent.」

「Sales of gastrointestinal products amounted to ¥1,701 million (up 17.4% year on year).」

「Gastrointestinal sales were ¥787 million, up 15.7% year on year. On a basis excluding the coronary intervention business, which ended in the fiscal year ended March 2024, sales were ¥747 million, up 25.0% year on year. The new bile duct tube stent model introduced in the first quarter received favorable clinical evaluations, and sales progressed at a pace exceeding expectations.」

「Excluding the coronary intervention business, which ended in the previous fiscal year, sales were ¥597 million, up 34.6% year on year. In addition to strong sales of the core bile duct tube stent, sales of colorectal stents grew significantly as the number of consignment facilities expanded.」

「Gastrointestinal-related sales increased 48.2% year on year. The REGULUS bile duct tube stent steadily increased its market share after its high delivery performance was well received. Sales of colorectal stents and radiofrequency ablation electrode needles for liver cancer treatment also remained firm.」

「In the gastrointestinal field, sales of the company's own REGULUS bile duct tube stent remained strong, securing a market share of approximately 10% within about one year of launch.」

「Gastrointestinal-related sales increased 61.6% year on year. In the first quarter, sales of the REGULUS bile duct tube stent launched in the previous fiscal year remained strong after receiving high evaluations from medical professionals. Sales of the arfa radiofrequency ablation electrode needle for liver cancer treatment also remained firm as the company promoted sales of its generator.」

「The company also positioned the biliary and pancreatic fields, comprising the biliary tract and pancreas, as a growth area within the gastrointestinal field and made a full-scale entry with its own products from the current fiscal year.」

「The company also launched a bile duct endoscope and related accessories in November 2022 as new in-house gastrointestinal products, marking its full-scale entry into the biliary and pancreatic fields.」

「From October 2022, we plan to sequentially launch multiple proprietary products in the biliary endoscopy field, including the DRES series centered on cholangioscopes, and will work to further strengthen our presence in gastroenterology.」

「Gastroenterology-related products performed well, driven by the expansion of consignment facilities for the colonic stent and the stomach and duodenal stent Jentlly Neo Duodenal Stent launched in the previous fiscal year. The radiofrequency ablation electrode needle for liver cancer, arfa, also performed well. The company plans to launch multiple proprietary products for the biliary and pancreatic fields in the second half of the fiscal year ending March 2023 and is currently preparing for the launch.」

「With the planned launch of biliary and pancreatic products in the second half of the fiscal year ending March 2023, we will accelerate the full-scale development of the gastroenterology business and grow it into our second core business after cardiovascular care.」

「In gastroenterology, sales of our proprietary radiofrequency ablation electrode needle for liver cancer, arfa, and the colonic stent Jentlly Neo Colonic Stent increased significantly from the same period of the previous year as development of new facilities progressed. In addition, sales of the new stomach and duodenal stent Jentlly Neo Duodenal Stent began in September 2021, and we will further develop the gastroenterology field.」

「In gastroenterology, sales of our proprietary radiofrequency ablation electrode needle for liver cancer, arfa, and the colonic stent Jentlly Neo Colonic Stent increased significantly from the same period of the previous year as development of new facilities progressed. In addition, limited sales of the new stomach and duodenal stent Jentlly Neo Duodenal Stent began at selected facilities in September 2021.」

「We regard gastroenterology as a new growth field for the future. As we plan to launch a stent for the stomach and duodenum during the second quarter of the consolidated accounting period, we will continue to focus on expanding this field.」

「We plan to make a full-scale entry into gastroenterology by launching a new product line for the biliary and pancreatic fields in the fiscal year ending March 2023, and will work to establish the sales structure.」

「Among other products, arfa, our proprietary radiofrequency ablation system for liver cancer and the only domestically manufactured product in the gastroenterology field, has steadily increased its sales volumes since sales began in December 2019, resulting in higher sales. Going forward, we will further develop this field together with the already adopted colonic stent Jentlly.」

「Among other products, arfa, our proprietary radiofrequency ablation system for liver cancer and the only domestically manufactured product in the gastroenterology field, has gradually gained market acceptance since sales began in December 2019, driving higher sales. Going forward, we will further develop this field together with the already adopted colonic stent Jentlly.」

「In gastroenterology, we began full-scale sales in December 2019 of arfa, a radiofrequency ablation system for liver cancer developed using our proprietary technology, and are focusing on developing the market.」

「We are also pursuing entry into other fields by applying the technology developed through the development and manufacture of medical devices for arrhythmia treatment. Following the colonic stent launched last year, we have focused on developing products for gastroenterology, including a liver cancer treatment device based on ablation catheter technology.」

「As a medium- to long-term challenge, we are also working to expand our proprietary products into overseas markets. In April this year, the first overseas case involving an open stent graft as an implantable medical device was performed in Taiwan. We will build an overseas track record while preparing for the start of sales in Europe. We have also begun construction of a plant in Malaysia and are preparing for the full-scale overseas expansion of our proprietary products. Similarly, as a medium- to long-term challenge, we are pursuing expansion into treatment fields outside cardiovascular care through applications of our proprietary technologies. We began sales of the colonic stent JENTLLY in June last year, marking our entry into gastroenterology.」

「We will also pursue the development of medical devices outside the cardiovascular field by leveraging the technology and experience gained through developing our proprietary products. As part of these efforts, we planned to export open stent grafts to Europe and enter the gastroenterology field with colonic stents in the fiscal year ending March 2018.」